Related Experiment Video
Updated: Sep 29, 2025
Sound Source Localization Testing in Single-sided Deafness Following Bone Conduction Intervention
Published on: December 20, 2024
Early surgical and audiologic outcomes of active, transcutaneous, osseointegrated bone-conduction hearing device
Michelle M Florentine1, Jordan Virbalas2, Dylan K Chan2
1Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, CA, USA; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Objective:
To assess the outcomes of pediatric Osia 2® System placements.
Methods:
We performed a retrospective chart review of primary and revision Osia 2® System surgical cases at two tertiary academic children's hospitals. Operative details and post-operative surgical and audiologic outcomes were recorded.
Results:
18 cases were performed on 14 children (mean age: 11.5 years, range 7-16) and included 9 primary surgeries and 9 revisions from BAHA Attract®, Connect® and Sophono® implants. Surgical planning for revision surgeries was complex due to prior incisions, implants, and bony contour. Post-operative aided audiograms revealed pure tone average (0.5-4 kHz) of 26.2 ± 2.5 dB HL (mean ± SD), with no high frequency roll-off (8 kHz aided threshold: 23.8 ± 7.5 dB HL). Two minor post-operative complications were identified.
Conclusion:
Bone-conduction hearing devices (BCHDs) are used to improve access to sound for children with conductive hearing loss, single-sided deafness, and aural atresia. Traditional passive, percutaneous abutment-based and transcutaneous magnet-based surgical BCHDs can be limited by skin complications and high-frequency acoustic attenuation. Recent availability of active, transcutaneous osseointegrated BCHD systems presents potential for improvement on both of these traditional limitations. Initial experience with the Osia 2® System demonstrates overall successful, uncomplicated placement with excellent audiologic outcomes. Revision cases require careful surgical planning. Further follow-up and comparative studies with other BCHDs are necessary to fully evaluate the effectiveness of the Osia 2® System.
